SCHEMBL5947263

SCHEMBL5947263

Clc1ccc2c(CCNCc3cccc(Oc4ccccn4)c3)c[nH]c2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.55
▸ HTR6 P50406 4/20 0.50
▸ HTR2A P28223 3/20 0.50
▸ HTR1A P08908 1/20 0.50
▸ DRD2 P14416 1/20 0.50
▸ HTR2C P28335 1/20 0.50
▸ HTR7 P34969 1/20 0.50
▸ BCHE P06276 2/20 0.46
▸ ACHE P22303 2/20 0.46
▸ MC5R P33032 1/20 0.46
▸ MC3R P41968 1/20 0.46
▸ MC1R Q01726 1/20 0.46
▸ SNCA P37840 2/20 0.44
▸ MAPT P10636 3/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ MEN1 O00255 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5947282 0.89 KMT2A (0.69) KMT2AHTR6HTR2AHTR1ADRD2
SCHEMBL5948004 0.87 KMT2A (0.62) KMT2AHTR6HTR2AHTR1ADRD2
SCHEMBL5947348 0.86 KMT2A (0.55) KMT2AHTR6HTR2AHTR1ADRD2
SCHEMBL5947163 0.85 KMT2A (0.54) KMT2AHTR6HTR2AHTR1ADRD2
SCHEMBL27595977 0.83 HTR6 (0.50) KMT2AHTR6HTR2AHTR1ADRD2
SCHEMBL5947445 0.83 HTR2A (0.68) KMT2AHTR6HTR2AHTR1AHTR7
SCHEMBL5947632 0.81 HTR6 (0.58) KMT2AHTR6HTR2AHTR1ADRD2
SCHEMBL5947582 0.81 KMT2A (0.59) KMT2AHTR6HTR2AHTR1ADRD2
SCHEMBL5947492 0.80 HTR1A (0.56) KMT2AHTR2AHTR1AMAPTMAPK1
SCHEMBL5947738 0.80 KMT2A (0.48) KMT2AHTR6HTR2AHTR1ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor CHEN ZHAOGEN 2006-01-12 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor HTR6, HTR2C, HTR1B KMT2A 1269/4885HTR6 1/4885HTR2A 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback